Emerging analyses on retatruded, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate significant results in treating obesity and type 2 glucose intolerance. Preliminary evidence from clinical trials reveal substantial decreases in body weight and bettered gluc